Strategic Partnership to Drive Sustainable and Future-Ready Automotive Innovation

KAWASAKI, Japan and PUNE, India, Nov. 18, 2024 /PRNewswire/ — Suzuki Motor Corporation, a Japanese multinational mobility manufacturer, and Tata Elxsi, a global leader in design and technology services, today inaugurated the ‘SUZUKI-TATA ELXSI Offshore Development Center’ in Pune, India. This dedicated center will drive Suzuki’s innovations in advanced engineering, shaping the future of mobility.

Tata Elxsi will support Suzuki in its green mobility vision by aligning with Suzuki’s goals for sustainable innovation in lightweight design, safety, styling and engineering, eco-friendly materials, and advanced simulations to improve time-to-market. The partnership will also focus on next-generation powertrains and software-defined vehicles, fostering energy-efficient solutions for electric, hybrid, and alternative fuel vehicles.

At the inauguration, Suzuki’s Chief Technology Officer, Katsuhiro Kato, highlighted the importance of the center as a core component of Suzuki’s innovation strategy. “As the industry progresses in Connected, Autonomous, Shared, and Electric technologies, Suzuki must accelerate electronic and virtual development to meet evolving demands. Tata Elxsi’s expertise in advanced computing, simulation, and design digital makes them an ideal partner in bringing forward-thinking solutions to market. This strategic and long-term partnership incorporates Suzuki’s endeavor of minimising energy and enables India’s talent to actively contribute to our development efforts globally,” said Mr. Kato.

Manoj Raghavan, MD & CEO of Tata Elxsi, shared, “The inauguration of SUZUKI-TATA ELXSI Offshore Development Center marks a significant milestone in our partnership with Suzuki and our shared vision for the future of mobility. Tata Elxsi’s design-led, digital-first approach is uniquely positioned to support Suzuki’s energy minimisation and sustainability goals, advancing the future of automotive engineering with precision and responsibility. We are delighted to support Suzuki in this journey towards transformative automotive engineering.”

About Tata Elxsi

Incorporated in 1989, Tata Elxsi is amongst the world’s leading providers of design and technology services in select industries, including Automotive, Media & Telecom, Healthcare, and Transportation. Tata Elxsi works with leading OEMs and suppliers in the automotive and transportation industries for R&D, design, and product engineering services from architecture to launch and beyond. It combines domain experience across Autonomous, Electric, and Connected vehicle technologies and Software-defined vehicles (SDV). It is supported by a worldwide network of design studios, development centres, offices, and a global pool of over 13000 engineers and specialists.

For more information, visit www.tataelxsi.com.

About Suzuki

Suzuki Motor Corporation is one of Japan’s leading carmakers and a global motorcycle manufacturer. The company’s non-vehicle products include outboard motors for boats and motorized wheelchairs. It builds its lineup on its own and through numerous subsidiaries and joint ventures outside Japan. Suzuki was established in 1920 and has headquarters in Hamamatsu, Shizuoka. Toshihiro SUZUKI is President of the company.

Website: https://www.globalsuzuki.com

Logo: https://mma.prnewswire.com/media/742257/4913784/Tata_Elxsi_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/suzuki-and-tata-elxsi-launch-suzuki-tata-elxsi-offshore-development-center-302308277.html

SOURCE Tata Elxsi

New report analyses Mainland China’s transformation into a global biopharma powerhouse, with key insights for international stakeholders

LONDON, Nov. 18, 2024 /CNW/ — Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the release of a new report, A Decade of Innovation, A Decade to Come.

Over the past decade, Mainland China’s biopharmaceutical sector has rapidly advanced to become a global leader in innovation, ranking among the top three for initial drug launches. Driven by reforms, increased investment, and progressive policies, the industry has reduced approval timelines, raised regulatory standards, and improved patient access to advanced therapies. Insights from the Institute for Scientific Information™ show that China’s Gross Expenditure on Research and Development has grown 3.5 times over the past decade, outpacing growth rates in the UK and the U.S.1 These developments, combined with an evolving healthcare reimbursement system, have enabled both domestic and multinational companies to bring new therapies to market, benefiting millions of patients.

Henry Levy, President, Life Sciences & Healthcare, Clarivate, said: “Mainland China’s ascent in the biopharma sector reflects the power of sustained investment and strategic reform. This report not only highlights the impressive achievements of the past decade but also underlines the far-reaching potential for Chinese biopharma companies to drive global medical innovation and enhance patient outcomes worldwide.”

Tan Yong, Vice President of China Pharmaceutical Enterprises Association and Publisher of Healthcare Executive, noted: “The pharmaceutical industry is poised for significant and transformative changes in the upcoming decade, driven by heightened competition. Rapid innovation and intense competition have reshaped market dynamics, leading to more focused and sustainable growth. The report offers the industry a glimpse of how Chinese pharmaceutical companies can prioritize innovation and international expansion in the next decade.”

Alice Zeng, Senior Solution Consultant, Life Sciences & Healthcare, Clarivate, added: “This report is an invaluable resource for global industry stakeholders. For pharma companies worldwide, it provides a timely understanding of Mainland China’s biopharma landscape, covering the opportunities for international collaboration and the potential for accelerated market entry.”

The report highlights Mainland China’s regulatory advancements, rapid drug launch growth, and expanding domestic R&D role. Key updates include the National Reimbursement Drug List (NRDL), where systematic price negotiations have cut costs by 50-60%, improving access to innovative drugs. Additionally, Mainland China’s share of global licensing and service deals has grown from 6.5% to nearly 9% since 2015, and the country now leads in publishing research and filing patents in key life sciences, underscoring its rising influence on the global industry.

Key insights in A Decade of Innovation, A Decade to Come, include:

Impactful policy reforms: How regulatory initiatives such as the Marketing Authorization Holder (MAH) system and priority review programs have streamlined approvals and bolstered R&D.Healthcare accessibility and innovation: An examination of Mainland China’s healthcare reforms, including the expansion of the NRDL and commercial health insurance, increasing access to cutting-edge therapies.Investment and R&D growth: Analysis of Mainland China’s record-breaking R&D investment, driving advancements in oncology, anti-infectives, and emerging therapeutic areas.Global Integration and market opportunities: Insights into the rise of Mainland China’s biopharma sector as a global player, including the increase in multinational collaborations and first-to-market launches.

With Mainland China’s share of first-time global drug launches growing, and as new therapeutic areas advance, A Decade of Innovation, A Decade to Come provides timely, in-depth insights for international investors, multinational pharmaceutical companies, and healthcare stakeholders who seek to understand Mainland China’s role in shaping the future of the biopharma landscape.

The A Decade of Innovation, A Decade to Come report draws on comprehensive data and tools trusted by the global life sciences community, including Cortellis Competitive Intelligence, Cortellis Regulatory Intelligence™, Disease Landscape & Forecast, Cortellis Deals Intelligence, Cortellis Clinical Trials Intelligence™, Cortellis Product Intelligence™, Real World Data and Analytics, Access and reimbursement payer studies, BioWorld™, Web of Science™ and Derwent Innovation™ among others. Compiled by Clarivate analysts using data gathered prior to August 31, 2024, this report reflects Clarivate’s commitment to supporting drug, device, and medical technology lifecycles. By combining patient journey data, therapeutic insights, and AI-driven analytics, Clarivate enables evidence-based decisions that advance human health.

To learn more about the Clarivate report, A Decade of Innovation, A Decade to Come, visit here.

About Healthcare Executive
With media as the outpost, conference as the platform, live video broadcasting as the tool, and expert pharmaceutical industry observers and recorders as the living force, Healthcare Executive (E药经理人) brings the top consensus of entrepreneurs, scientists, and investors in the pharmaceutical industry together on the one hand, and on the other hand gathers multi-dimensional and multi-level resources from the whole industry chain. We are dedicated to providing in-depth professional communication opportunities and influential solutions for the whole industry chain in their whole life cycle. In this regard, we make connections with client requirements upstream and downstream and make preparations for the overseas strategy in their international programs.

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Media Contact 
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
Clarivate
newsroom@clarivate.com

1 Source: Global Research Report: China’s research landscape, ISI, Clarivate

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-report-from-clarivate-and-healthcare-executive-explores-mainland-chinas-biopharma-revolution-and-increasing-global-influence-302307317.html

SOURCE Clarivate Plc

LONDON, Nov. 18, 2024 /PRNewswire/ — Fastmarkets, a leading cross-commodity price-reporting agency, is excited to announce their strategic partnership with Gulf Mercantile Exchange Limited (GME). Fastmarkets and the GME have agreed a Memorandum of Understanding (MOU) to explore a strategic partnership aimed at enhancing risk management tools for the regional commodities market. This collaboration will focus on critical commodities and aims to advance commodity risk management, market transparency and educational initiatives.

The GME and Fastmarkets will explore collaboration across areas including new commodity derivatives, indices and hedging instruments tailored to meet the needs of regional markets. Additionally, the collaboration will focus on promoting education and fostering industry dialogue by organizing and co-hosting networking events, seminars and workshops on commodity trading, risk management and pricing strategies.

The region is expanding rapidly due to increased investment in infrastructure and diversification of the economy, positioning Fastmarkets as the trusted provider to deliver the essential tools and insights needed to navigate this growth effectively.

“We are excited to partner with Fastmarkets to bring innovative solutions to the regional commodities market,” chairman of GME Ahmad Sharaf said.

Fastmarkets is at the forefront of innovation, consistently delivering comprehensive solutions that address the evolving needs of the commodities industry, ensuring customers have reliable data and tools for informed decision-making. Through its commitment to regional support, Fastmarkets is driving growth and expansion, fostering a resilient commodities market that meets local demand and opens up new avenues for economic development and trade.

Raju Daswani, CEO of Fastmarkets, added: “This partnership represents a significant step forward in supporting the growth and development of the regional commodities market. We look forward to working together to achieve our shared goals and deliver value to our stakeholders.”

Find out how Fastmarkets can help you or email media@fastmarkets.com to connect with our team.

ABOUT FASTMARKETS

Fastmarkets is an industry-leading PRA and information provider for the agriculture, forest products, metals and energy transition commodities’ markets. Fastmarkets serves its customers with commodity benchmark prices and assessments, forecasts, analytics, insights, news and events. Its data is critical for customers seeking to understand and predict dynamic, sometimes opaque markets, enabling trading and risk management.
Fastmarkets is a global business with a history dating from 1865 and is built on trust and deep market expertise. It has more than 650 employees spread across several global locations including the UK, US, China, Singapore, Brazil, Bulgaria, Belgium, Ukraine and Finland.
Fastmarkets is a privately held UK-registered company owned by its shareholders and Astorg, a European private equity firm.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fastmarkets-and-gulf-mercantile-exchange-forge-strategic-partnership-to-innovate-commodity-risk-management-tools-in-the-region-302307014.html

SOURCE Fastmarkets